Danish Luxury Stock News

If you are eyeing H. Lundbeck stock and trying to decide whether now is the right time to move, you are not alone. Investors have noticed the recent uptick, with shares climbing 5.6% in the past week and 12.6% over the last month. Year to date, the return is a solid 6.9%. What really stands out is the 91.1% gain over the past three years. Clearly, the market has warmed up to Lundbeck, giving some the sense that the momentum could continue, or perhaps that all the easy gains are already...

ALK-Abelló recently announced a partnership with Changchun GeneScience Pharmaceutical Co. Ltd. (GenSci) to develop and commercialise its house dust mite allergy immunotherapy portfolio in Mainland China, granting GenSci exclusive rights until 2039 and transferring marketing, sales, and most clinical responsibilities to the local partner. This agreement aims to unlock significant potential in China’s under-tapped allergy immunotherapy market and allows ALK to reallocate resources to...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

TORM plc's ( CPH:TRMD A ) price-to-earnings (or "P/E") ratio of 6.6x might make it look like a strong buy right now...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Pandora fair value estimate is kr.1,452 Pandora is estimated...

Zealand Pharma (CPSE:ZEAL) Stock Movement Raises Valuation Questions If you follow biotech stocks, you might have noticed Zealand Pharma (CPSE:ZEAL) making some moves lately. There has not been a specific event grabbing headlines, but the stock's action could have investors wondering if something meaningful is brewing under the surface. When a company's shares shift gears without an obvious spark, it is often a cue to dig a little deeper into what is driving sentiment and whether the market...

If you’ve been watching H. Lundbeck (CPSE:HLUN B) lately, you might be wondering what’s behind the recent wave of interest in the stock. While there hasn’t been a headline-grabbing event to push shares in a new direction, the stock’s activity could be catching investors’ attention for other reasons. With shares trading right around 45 DKK, even subtle moves can spark curiosity about whether the market is signaling a shift in its view of the Danish pharma specialist. Over the past year, H...

One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...

Earlier this month, HBM Healthcare Investments announced that its portfolio company Swixx BioPharma signed a multi-regional distribution and services agreement with H. Lundbeck A/S, covering Lundbeck's central nervous system portfolio in South-East Europe, Turkey, and Latin America, as part of a wider transition by Lundbeck to a partnership-based commercial operating model in 27 international markets with Swixx Group, Zuellig Pharma, and NewBridge Pharmaceuticals. This shift reflects a...

Key Insights Netcompany Group's estimated fair value is kr.396 based on 2 Stage Free Cash Flow to Equity Current share...

If you are building a properly diversified stock portfolio, the chances are some of your picks will perform badly. Long...

ChemoMetec A/S ( CPH:CHEMM ) shares have had a really impressive month, gaining 26% after a shaky period beforehand...

Deciding what to do with NKT stock right now might feel a bit like standing at a crossroads. Maybe you’re eyeing those recent price gains and wondering if there’s still more upside ahead, or perhaps you’re cautious after such a strong run. Over the past week, NKT shares have ticked up by 1.6%, and looking a bit further back, the 30-day return sits at an impressive 5.3%. Year-to-date, the stock has soared by 20.5%. If you zoom out even more, the long-term story gets even more interesting, with...

Deciding what to do with Rockwool stock? You are definitely not alone—it is one of those companies that always sparks debate among investors, especially after a stretch of ups and downs that has put everyone on alert. If you have been watching the chart, you know things have been anything but boring. After a relatively flat week, the share price has taken a 15.3% drop over the past month and sits down 5.1% for the year. Over the past year, Rockwool is off 14.6%, but zoom out to three years...

TROPHY GAMES Development A/S ( CPH:TGAMES ) shares have retraced a considerable 28% in the last month, reversing a fair...

H. Lundbeck (CPSE:HLUN B) has recently seen its shares catch a bit of attention, even without a dramatic headline to drive the move. Sometimes, the absence of an obvious trigger can raise just as many questions as a major announcement. It prompts investors to dig a little deeper, asking whether traders are anticipating future news, simply reacting to broader market currents, or reading more subtle signals about Lundbeck’s future prospects. Looking back at the year, there has been a...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

GN Store Nord A/S ( CPH:GN ) shareholders should be happy to see the share price up 22% in the last month. But will...

Vestas Wind Systems (CPSE:VWS) just landed a fresh order that is bound to catch the eye of investors weighing their next move. The company announced a deal with Energiekontor AG in Germany, supplying 13 of its V162-7.2MW turbines and committing to a long-term, 20-year service agreement. While this order itself may not shift the industry's foundations, the combination of scale and a substantial service window signals ongoing appetite for Vestas’ solutions in the key EMEA region. This can be...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

It is hard to get excited after looking at DSV's (CPH:DSV) recent performance, when its stock has declined 17% over the...

Key Insights The considerable ownership by retail investors in Pandora indicates that they collectively have a greater...

Cemat A/S' ( CPH:CEMAT ) robust earnings report didn't manage to move the market for its stock. We did some digging...

Investors in Novo Nordisk (CPSE:NOVO B) have just gotten a major jolt with fresh data from the STEER real-world study, presented at the European Society of Cardiology Congress 2025. The company’s obesity drug Wegovy showed a strikingly greater reduction in risk for serious cardiovascular events compared to tirzepatide, among people living with obesity and established cardiovascular disease but no diabetes. With a 57% greater risk reduction for heart attack, stroke, and deaths from any cause...